Evidence map›Paper›PMID 42404647›Full record

ArticleOpen medicine (Warsaw, Poland)2026

Evaluation of serum moesin and podocalyxin levels in patients with diabetes mellitus.

Selin Genc, Oguzhan Aksu, Ummugulsum Can, Hatice Caliskan Burgucu, Selma Ozlem Celikdelen, Jelena Kotur Stevuljevic, Aleksandra Klisic, Enver Ciftel, Filiz Mercantepe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Selin GencDepartment of Endocrinology and Metabolism, Konya State Hospital, Konya, Türkiye.ORCID https://orcid.org/0000-0001-5525-3476
Oguzhan AksuDepartment of Endocrinology and Metabolism, Konya State Hospital, Konya, Türkiye.ORCID https://orcid.org/0000-0003-4666-7129
Ummugulsum CanDepartment of Biochemistry, Konya State Hospital, Konya, Türkiye.ORCID https://orcid.org/0000-0002-8967-2924
Hatice Caliskan BurgucuDepartment of Endocrinology and Metabolism, Konya State Hospital, Konya, Türkiye.ORCID https://orcid.org/0000-0001-7699-4580
Selma Ozlem CelikdelenDepartment of Internal Medicine, Konya State Hospital, Konya, Türkiye.ORCID https://orcid.org/0009-0000-8546-0070
Jelena Kotur StevuljevicDepartment for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.ORCID https://orcid.org/0000-0002-6980-3069
Aleksandra KlisicDepartment of Biochemistry, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro.
Enver CiftelDepartment of Endocrinology and Metabolism, Sivas Numune Hospital, Sivas, Türkiye.ORCID https://orcid.org/0000-0003-1431-5663
Filiz MercantepeDepartment of Endocrinology and Metabolism, Faculty of Medicine, Duzce University, Duzce, Türkiye.ORCID https://orcid.org/0000-0002-4325-1534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Diabetic nephropathy (DN) is a major microvascular complication of diabetes and a leading cause of end-stage renal disease. Reliable biomarkers for early DN detection remain limited. Moesin and podocalyxin, involved in endothelial and podocyte integrity, may contribute to DN pathophysiology. This study evaluated whether serum moesin and podocalyxin levels differ according to the presence of early-stage DN in type 2 diabetes. Methods: In this single-center cross-sectional study, 63 patients with type 2 diabetes and 27 healthy controls were included. Diabetic participants were classified as normoalbuminuric diabetes (DM) or microalbuminuric early DN (DNP) based on spot urine albumin-to-creatinine ratio. Serum moesin and podocalyxin levels were measured by ELISA. Group comparisons and regression analyses were performed. Results: Both biomarkers were significantly lower in diabetic patients than in controls (p<0.001), but no difference was observed between DM and DNP after age adjustment. Neither biomarker independently predicted nephropathy. A composite factor including moesin, podocalyxin, age, white blood cell count, and microalbuminuria was associated with DN (OR 4.03, 95 % CI 1.42-11.47, p=0.009). Conclusions: Serum moesin and podocalyxin decrease in type 2 diabetes but do not independently distinguish early DN, suggesting limited kidney-specific utility.

Indexed as

biomarkersdiabetic nephropathyendothelial dysfunctionmoesinpodocalyxinpodocyte injury

Identifiers

PMID42404647
PMCPMC13328042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.